Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
Holding PSNL?
Track your performance easily
PSNL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.89 - $7.20
Previous Close$5.11
Volume536.25K
Average Volume (3M)1.51M
Market Cap
$271.21M
Enterprise Value$220.76M
Total Cash (Recent Filing)$86.97M
Total Debt (Recent Filing)$36.52M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Nov 06, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding65,920,000
10 Day Avg. Volume559,216
30 Day Avg. Volume1,505,573
Standard Deviation0.33
R-Squared0.09
Alpha-0.00357
Financial Highlights & Ratios
Price to Book (P/B)3.06
Price to Sales (P/S)4.21
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit12.12
Enterprise Value/Ebitda-4.57
Forecast
1Y Price Target
$7.05Price Target Upside35.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Personalis News
PremiumCompany Announcements
Personalis Strengthens Market Position with Tempus DealBulls Say, Bears Say
Bulls Say
Market OpportunityShares have drifted from their highs earlier in the year and since the release of the ASCO data, creating a buying opportunity.
Product LaunchThe recent clinical launch of NeXT Personal Dx into the minimal residual disease (MRD) testing market sets the stage for data generation and publication, reimbursement applications, and, ultimately, adoption by the oncology community.
Revenue GrowthThe company increased 2024 revenue guidance to $76M-$78M from $73M-$75M.
Bears Say
Commercialization And ReimbursementA modestly discounted multiple relative to comparable companies is warranted given the early stage of the Company’s transformation toward the commercialization of NeXT Personal Dx and the lack of reimbursement for NeXT Personal Dx.
Revenue GrowthRevenue growth slowed to 4% Y/Y in 1Q24 from 18% in 4Q23 as Oncology growth and V A MVP revenue growth both slowed.
Stock PerformanceThe substantive changes implemented by the Company have not been reflected in shares which have traded down 48% since Chris Hall’s installation as CEO.
---
Ownership Overview
31.89% Insiders
6.78% Mutual Funds
0.14% Other Institutional Investors
44.34% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $0.89 and its highest was $7.20 in the past 12 months.
What is Personalis Inc’s market cap?
Currently, no data Available
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Nov 06, 2024 which is in 22 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Aug 07, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.373 by $0.133.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -$0.35.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 53,074,700 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.373. Following the earnings report the stock price went up 19.097%.
Which hedge fund is a major shareholder of Personalis Inc?
Among the largest hedge funds holding Personalis Inc’s share is ARK Investment Management LLC. It holds Personalis Inc’s shares valued at 7M.
---
Personalis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.05 (35.32% Upside)
$7.05 (35.32% Upside)
Hedge Fund Trend
Increased
By 296.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $36.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
336.75%
12-Months-Change
Fundamentals
Return on Equity
-56.49%
Trailing 12-Months
Asset Growth
-25.51%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
---
PSNL Earnings Call
Q2 2024
0:00 / 0:00
---
PSNL Stock 12 Month Forecast
Average Price Target
$7.05
▲(35.32% Upside)
Technical Analysis
Best Analysts Covering PSNL
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+120.48%
reiterated a buy rating 2 months ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +120.48% per trade.
---